Anup Kundu PhD

Anup Kundu PhD

Assistant Professor, Department of Biology

Kundu lab at Xavier University of Louisiana works in the highly interdisciplinary areas of nanoparticle formulation, characterization and targeted delivery of drugs and genes into breast cancer cells. The development of multidrug resistance (MDR) in cancer cells is of grave concern, limiting the efficacy of anticancer agents and, hence, the failure of breast cancer therapy. Clinical research and application revealed that in spite of it’s potential anticancer effects, doxorubicin is highly toxic, and its long-term application may cause dose-dependent irreversible cardiomyopathy, severe cardiac toxicity, or liver damage, thereby limiting its application in breast cancer treatment. As such, the greater potential of using doxorubicin as anticancer therapeutic depends on the availability of a targeted delivery vehicle, which will not only enhance the killing of cancer cells but also minimize the off-target toxicity to non-cancerous cells.

The goal of Kundu lab at Xavier University of Louisiana is to enhance the delivery of doxorubicin by formulating an aptamer-labeled liposomal nanoparticle delivery system that will carry and deliver doxorubicin specifically into chemo resistant breast cancer cells.

SelectedPublications:

1.      Powell D, ChandraS, Dodson K, Shaheen F, Wilt K, Ireland S, Syed M, Dash D, Wiese T, Mandal,T.K., Kundu, A.K. (2017)Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer. Eur J of Pharmaceutics and Biopharmaceutics114: 108–118.

2.      *GopalakrishnanAM, *Kundu AK, Mandal TK, Kumar N. (2013)Novel nanosomes for gene delivery to Plasmodium falciparum-infected red blood cells. Scientific Reports. 3:1534.

3.      Chandra PK, KunduAK, Hazari S, Chandra S, Bao L, Ooms T, Morris GF, Wu T, Mandal TK, Dash S. (2012) Inhibition of hepatitis C virus replication by intracellular delivery of multiple siRNAs by nanosomes. Molecular Therapy. 20(9): 1724-36.

4.      Chowdhury N,Olverson G, Hall N, Chaudhry S, Dash S, Mandal T, *Kundu A. (2020) Targeted Delivery of Doxorubicin Liposomes for Her-2 Positive Breast Cancer Treatment. AAPS PharmSciTech. (2020) 21:202, 2-12.

 

Keywords/Tags: Nanoparticles; nanoscaffolds, drug/gene delivery, cancer, targeted therapy

LCRC Faculty

Samuel J. Landry PhD
Translational Oncology
Tulane University School of Medicine
Elisa Ledet, PhD
Translational Oncology
Tulane University School of Medicine
Sean Bong Lee PhD
Cancer Biology
Tulane University School of Medicine
KiTani Lemieux PhD
Population Sciences
Xavier University
Brian Lewis, Phd
Translational Oncology
Tulane University School of Medicine
Li LI MD PhD
Cancer Biology
Ochsner Health
Zhen Lin MD PhD
Genes X Environment
Tulane University School of Medicine
Hui-Yi Lin PhD
Population Sciences
LSU Health - New Orleans
Yong-Yu Liu PhD
Translational Oncology
University of Louisiana Monroe